Safety Study of Erythropoietin (EPO) in Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Registration Number
- NCT01010802
- Lead Sponsor
- International Center for Neurological Restoration, Cuba
- Brief Summary
The purpose of this study is to determine whether recombinant human Erythropoietin (EPOrh) is safe in the treatment of patients with Parkinson's Disease.
- Detailed Description
After onset of Parkinson's Disease (PD)- in spite of the use of medications that constitute the symptomatic treatment- the disease is worsens with an inevitable progression, thus causing complications that lead to the loss of patient´s manual skills and independent gait. At present, the treatment of PD with the use of medications is based on dopamine precursors and dopaminergic agonists but as the disease advances, other symptoms that do not respond to dopaminergic stimulation do appear.
For this reason, it is a priority to find a way to focus on neuroprotection during the course of the disease. There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO).
Positive results on the neuroprotective/neurotrophic efficacy of EPO in neurological and psychiatric diseases have been obtained from treatment trials, but nevertheless, it is indispensable demonstrate that with the proposed medication doses it's well tolerated by PD patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
- Hohen and Yahr´s Scale between I and III
- One or more years of evolution of PD,
- Good response to levodopa (more that 30 % of change)valued in motor UPDRS
- An acceptable general health status,
- Chronic psychiatric or other neurological diseases.
- Previous polyglobulin
- Hematocryte, same or inferior to 50
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Erythropoietin Erythropoietin human recombinant (EPOrh) There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms. EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin.
- Primary Outcome Measures
Name Time Method safety assessment measured by the absence of adverse events weeks 1 to 5, 6, 12, 23 and 35
- Secondary Outcome Measures
Name Time Method Post-treatment change in the motor score of the Unified Assessment Scale for Parkinson Disease´s (UPDRS) in the "OFF" condition as compared with the baseline. week 6, 12, 23 and 35
Trial Locations
- Locations (1)
Clinic of Movement Disorders, International Center for Neurological Restoration
🇨🇺Havana, Cuba